247 related articles for article (PubMed ID: 32272891)
1. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis.
Li X; Sheng L; Liu L; Hu Y; Chen Y; Lou L
BMC Gastroenterol; 2020 Apr; 20(1):98. PubMed ID: 32272891
[TBL] [Abstract][Full Text] [Related]
2. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
[TBL] [Abstract][Full Text] [Related]
4. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
[TBL] [Abstract][Full Text] [Related]
5. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Goh MJ; Sinn DH; Kim S; Woo SY; Cho H; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Hepatology; 2020 Jun; 71(6):2023-2032. PubMed ID: 31556128
[TBL] [Abstract][Full Text] [Related]
6. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
7. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?
Lok AS
J Gastroenterol Hepatol; 2011 Feb; 26(2):221-7. PubMed ID: 21070361
[TBL] [Abstract][Full Text] [Related]
8. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
[TBL] [Abstract][Full Text] [Related]
9. Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis.
Li Z; Li Y; Li X; Zhang L; Zhao N; Du H; Zhou B; Ye Y
Turk J Gastroenterol; 2022 Feb; 33(2):136-144. PubMed ID: 35115293
[TBL] [Abstract][Full Text] [Related]
10. Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis.
Li Z; Li Y; Li X; Zhang L; Zhao N; Du H; Zhou B; Ye Y
Medicine (Baltimore); 2018 Aug; 97(34):e11950. PubMed ID: 30142817
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection.
Aljumah AA; Kuriry H; Faisal N; Alghamdi H
Ann Saudi Med; 2018; 38(5):358-365. PubMed ID: 30284991
[TBL] [Abstract][Full Text] [Related]
12. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
[TBL] [Abstract][Full Text] [Related]
13. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection.
Lu T; Seto WK; Zhu RX; Lai CL; Yuen MF
World J Gastroenterol; 2013 Dec; 19(47):8887-94. PubMed ID: 24379612
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Alfaiate D; Clément S; Gomes D; Goossens N; Negro F
J Hepatol; 2020 Sep; 73(3):533-539. PubMed ID: 32151618
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic viruses and hepatocellular carcinoma.
Ben Ari Z; Weitzman E; Safran M
Clin Liver Dis; 2015 May; 19(2):341-60. PubMed ID: 25921667
[TBL] [Abstract][Full Text] [Related]
16. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.
Chen CL; Yang HI; Yang WS; Liu CJ; Chen PJ; You SL; Wang LY; Sun CA; Lu SN; Chen DS; Chen CJ
Gastroenterology; 2008 Jul; 135(1):111-21. PubMed ID: 18505690
[TBL] [Abstract][Full Text] [Related]
17. Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis.
Li X; Liu L; Hu Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32162652
[TBL] [Abstract][Full Text] [Related]
18. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.
Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT
Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695
[TBL] [Abstract][Full Text] [Related]
19. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
Tsan YT; Lee CH; Wang JD; Chen PC
J Clin Oncol; 2012 Feb; 30(6):623-30. PubMed ID: 22271485
[TBL] [Abstract][Full Text] [Related]
20. Statin-Based Palliative Therapy for Hepatocellular Carcinoma.
Shao JY; Lee FP; Chang CL; Wu SY
Medicine (Baltimore); 2015 Oct; 94(42):e1801. PubMed ID: 26496314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
